Clinical Trial Details

Overview

Research Study Summary

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE

Purpose
Receive Ubrogepant or placebo for treatment of migraines
To Learn more

CW ID: 222816
Date Last Changed: February 3, 2017

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
18 to 74 Years
Overall Status
Recruiting
Lead Sponsor
Allergan
Duration
16 Weeks
Facility Type
Out-Patient

Eligibility

Migraines for at least a year

Contact

Herenia Sanchez-Lacayo, CRC, Primary Assigned Coordinator
Clinical Research of South Florida
370 Minorca Avenue
Coral Gables, FL 33134
Phone: 305-445-5637-245
Fax: 305-445-5815

View Map

Research Center Information:

Clinical Research of South Florida

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.